Evidence map›Paper›PMID 11134315›Full record

ArticleJournal of virology2001

Accumulation of herpes simplex virus type 1 early and leaky-late proteins correlates with apoptosis prevention in infected human HEp-2 cells.

M Aubert, S A Rice, J A Blaho

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 75 citations in OpenAlex.

  1. Cell death network regulation in HSV infection: immune evasion versus host defense.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Article
  3. Article
  4. Viral and cellular mRNA-specific activators harness PABP and eIF4G to promote translation initiation downstream of cap binding.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

M AubertDepartment of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, USA.
S A Rice
J A Blaho
Icahn School of Medicine at Mount Sinai · USUniversity of Minnesota Medical Center · US

Funding

MOLECULAR CHARACTERIZATION OF HERPES SIMPLEX VIRUS ICP27R01AI042737 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI RICE, STEPHEN A · 1998 to 2014
$3.2M
HSV REGULATION BY PROTEIN MODIFICATIONR01AI038873 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BLAHO, JOHN A. · 2002 to 2006
$1.5M
HSV REGULATION BY PROTEIN MODIFICATIONR21AI038873 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BLAHO, JOHN A. · 2001 to 2001
$339k
Molecular Characterization of Herpes Simplex Virus ICP27R21AI042737 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI RICE, STEPHEN A · 2003 to 2003
$240k
HSV PROTEIN NUCLEOTIDYLATION AND LYTIC INFECTIONR29AI038873 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BLAHO, JOHN A. · 1996 to 2000
$117k
NIAID NIH HHS AI38873NIAID NIH HHS AI42737NIAID NIH HHS R01 AI038873NIAID NIH HHS R01 AI042737NIAID NIH HHS R21 AI038873NIAID NIH HHS R21 AI042737NIAID NIH HHS R29 AI038873
6 · The paper itself

Abstract

We previously reported that a recombinant ICP27-null virus stimulated, but did not prevent, apoptosis in human HEp-2 cells during infection (M. Aubert and J. A. Blaho, J. Virol. 73:2803-2813, 1999). In the present study, we used a panel of 15 recombinant ICP27 mutant viruses to determine which features of herpes simplex virus type 1 (HSV-1) replication are required for the apoptosis-inhibitory activity. Each virus was defined experimentally as either apoptotic, partially apoptotic, or nonapoptotic based on infected HEp-2 cell morphologies, percentages of infected cells with condensed chromatin, and patterns of specific cellular death factor processing. Viruses d27-1, d1-5, d1-2, M11, M15, M16, n504R, n406R, n263R, and n59R are apoptotic or partially apoptotic in HEp-2 cells and severely defective for growth in Vero cells. Viruses d2-3, d3-4, d4-5, d5-6, and d6-7 are nonapoptotic, demonstrating that ICP27 contains a large amino-terminal region, including its RGG box RNA binding domain, which is not essential for apoptosis prevention. Accumulations of viral TK, VP16, and gD but not gC, ICP22, or ICP4 proteins correlated with prevention of apoptosis during the replication of these viruses. Of the nonapoptotic viruses, d4-5 did not produce gC, indicating that accumulation of true late gene products is not necessary for the prevention process. Analyses of viral DNA synthesis in HEp-2 cells indicated that apoptosis prevention by HSV-1 requires that the infection proceeds to the stage in which viral DNA replication takes place. Infections performed in the presence of the drug phosphonoacetic acid confirmed that the process of viral DNA synthesis and the accumulation of true late (gamma(2)) proteins are not required for apoptosis prevention. Based on our results, we conclude that the accumulation of HSV-1 early (beta) and leaky-late (gamma(1)) proteins correlates with the prevention of apoptosis in infected HEp-2 cells.

Indexed as

AnimalsApoptosisCell SizeChlorocebus aethiopsDNA, ViralEpithelial CellsGene Expression Regulation, ViralHerpesvirus 1, HumanHumansImmediate-Early ProteinsImmunoblottingMicroscopy, Phase-ContrastMutationRecombination, GeneticTumor Cells, CulturedVero CellsDNA, ViralICP27 protein, human herpesvirus 1Immediate-Early ProteinsViral Proteins

Identifiers

PMID11134315
PMCPMC113998
OpenAlexW2010491850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.